fda glp-1 warning news november 2025 Weight-Loss Drug Demonstration Begins July 2026 New project announcement: HHS‑OIG is

FirneiszGVargaTLengyelGFehrJGhyczyDWichmannBet al

Alpha-glucosidase is an enzyme in the digestive system that facilitates the breakdown of dietary starches into simple sugars for intestinal absorption

Metabolic Mind is a nonprofit initiative of Baszucki Group where were providing information about the intersection of metabolic health and mental health and metabolic therapies such as nutritional ketosis as therapies for mental illness

Another trial demonstrated a significant reduction in body weight with the use of semaglutide, with subjects losing up to 14.9% of their initial body weight over a period of 68 weeks

We will discuss the risk of hypoglycemia, gastrointestinal side effects including previous reports on increased risk for pancreatitis and pancreas cancer, thyroid cancer, gallbladder stones, effects on the cardiovascular system, acute kidney injury, diabetic retinopathy risks and allergies/injection-site reactions ( Table 2 )